Immatics (4A3) AI Stock Analysis

3 Followers

Immatics

(XETRA:4A3)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Conservative leverageVery low leverage reduces solvency pressure while Immatics funds clinical development, giving the company more financial flexibility than a similarly loss-making biotech with substantial debt. This supports resilience against refinancing stress and preserves options for future capital allocation.

Negative Factors

Deep ongoing lossesSeverely negative margins show that current operating scale is far below the spending required to support the business. Until clinical programs or partnerships produce greater economic returns, persistent losses can consume capital and make earnings power difficult to assess or sustain.

Immatics (4A3) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 1.03B
Dividend Yield: ―
Average Volume (3M): 1,168
Price to Earnings (P/E): -3.9
Beta (1Y): 0.59
Revenue Growth: -67.95%
EPS Growth: -155.45%
Country: Germany
Employees: 704
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Immatics Business Overview & Revenue Model

Company Description

Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted im...

Immatics Risk Analysis

Immatics disclosed 84 risk factors in its most recent earnings report. Immatics reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk

1.Changes in the tax laws, or in their interpretation or enforcement, could have a material adverse effect on our financial condition and results of operations.Q4, 2023

Immatics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:4A3 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JANX	56Neutral	$1.09B	-11.02	-10.79%	―	5366.97%	8.50%
IMCR	54Neutral	$1.55B	-162.12	-2.35%	―	20.19%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SANA	49Neutral	$730.44M	-3.37	-134.49%	―	―	28.46%
AUTL	46Neutral	$376.61M	-1.30	-178.58%	―	287.93%	-21.91%
ALLO	38Underperform	$386.95M	-1.78	-50.04%	―	―	40.16%

* Healthcare Sector Average

Performance Comparison

DE:4A3 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:4A3	Immatics N.V.	6.18	-1.25	-16.76%
AUTL	Autolus Therapeutics	1.38	0.02	1.47%
ALLO	Allogene Therapeutics	1.19	0.14	13.33%
SANA	Sana Biotechnology, Inc.	2.56	-1.49	-36.79%
IMCR	Immunocore Holdings Plc	29.23	-2.36	-7.49%
JANX	Janux Therapeutics, Inc.	18.18	-10.48	-36.57%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Immatics AI Stock Analysis